3-Pyrrolidinecarboxylic Acid, 4-(3-Methoxyphenyl)-, (3S,4R)-

In the synthetic route to brain-penetrant aryl-pyrrolidine neurokinin-1 receptor antagonists, the enantiopure (3S,4R)-4-(3-methoxyphenyl)pyrrolidine-3-carboxylic acid operates as the chiral linchpin that establishes the trans 1,2-substitution geometry mandatory for sub-nanomolar binding at the human NK1 receptor. Multi-kilogram batches of the intermediate are manufactured under a quality system aligned with ICH Q7 and 21 CFR Part 211 guidelines for advanced pharmaceutical intermediates, with a batch-release specification that includes enantiomeric excess determined by chiral stationary-phase HPLC (Chiralpak IG‑3, 250×4.6 mm, 90:10 n‑hexane:ethanol + 0.1% trifluoroacetic acid, 1.0 mL/min, detection at 254 nm) meeting a criterion of ≥ 99.5% ee, residual palladium below 10 ppm (USP 〈232〉 by ICP‑MS), and water content ≤ 0.15% w/w (Karl Fischer coulometry). In the pivotal amide-bond-forming step, the acid is typically charged at 1.08–1.12 molar equivalents relative to the benzylamine nucleophile; the slight excess compensates for adventitious moisture retained in the N,N‑dimethylformamide solvent after vacuum distillation to a water specification of ≤ 150 ppm. Activation proceeds via pre-formed 2‑(1H‑benzotriazol‑1‑yl)‑1,1,3,3‑tetramethyluronium hexafluorophosphate (HBTU)/1‑hydroxybenzotriazole (HOBt) active ester in DMF at a jacket‑controlled internal temperature of 0–5°C, monitored for racemization risk by in‑line ReactIR tracking of the carbonyl stretch at 1740 cm⁻¹. After 25–30 min of pre‑activation in a 630 L glass-lined reactor equipped with a retreat-curve impeller at 75 rpm, the amine component dissolved in DMF is added over 45 min while maintaining the temperature below 5°C; the coupling is complete within 2 h as verified by TLC (ethyl acetate/n‑hexane 1:1 v/v, UV 254 nm). The resulting amide is telescoped through hydrogenolytic O‑demethylation (H₂, 3 bar, 10% Pd/C, 5% w/w loading) and hydrochloride salt formation to deliver the chiral intermediate of a selective NK1 antagonist that entered Phase II clinical assessment for chemotherapy‑induced nausea and vomiting. Operational boundaries dictate that the entire activation–coupling sequence be executed inside a 4‑h window because the α‑proton at C‑3 of the pyrrolidine ring is susceptible to base‑catalysed epimerisation; exposure to triethylamine at internal temperatures above 10°C for periods exceeding 1.5 h raises the C‑3 epimer content to over 1.8%, which cannot be corrected downstream by recrystallisation.

When the same (3S,4R) scaffold is deployed in the synthesis of µ‑opioid receptor biased agonists explored for pruritus management, the carboxylic acid is converted into a Weinreb amide before Grignard addition to generate an aryl ketone precursor. Compliance in this processing stream extends to the control of genotoxic impurities; as the 3‑methoxyphenyl substituent does not contain a secondary amine, the risk of nitrosamine formation is assessed according to the EMA/409815/2020 guideline and confirmed absent by spiking‑recovery experiments using a LC‑MS/MS method with a limit of quantification of 0.03 ppm. The Weinreb amide formation employs 1.0 equivalent of the acid, N,O‑dimethylhydroxylamine hydrochloride (1.3 eq), 1‑(3‑dimethylaminopropyl)‑3‑ethylcarbodiimide hydrochloride (1.3 eq), and HOBt (1.3 eq) in dichloromethane at −5°C, yielding the masked carbonyl after aqueous work‑up and silica‑gel filtration. Subsequent treatment with 3‑methoxyphenylmagnesium bromide (1.2 eq, 0.5 M in THF) at −20°C in a 500 L reactor, followed by a quench with 2 M aqueous ammonium chloride regulated to pH 7.0 ± 0.2, produces the ketone intermediate, which is then telescoped into asymmetric reductive amination using titanium(IV) isopropoxide and a chiral ruthenium catalyst [(R)‑RuCl[(p‑cymene)(Segphos)]Cl, 1 mol%] under 20 bar hydrogen. The terminal drug substance, isolated as the di‑p‑toluoyl‑L‑tartrate salt with 99.8% ee, acts as a G‑protein biased agonist at the µ‑opioid receptor and has reached an Investigational New Drug filing stage.

What Limits the Process Mass Intensity When This Pyrrolidine Acid Is Reduced to a Chiral Amino Alcohol?

The carboxyl group of (3S,4R)‑4‑(3‑methoxyphenyl)pyrrolidine‑3‑carboxylic acid can be reduced to a primary alcohol by lithium aluminium hydride in tetrahydrofuran, generating (3S,4R)‑3‑(hydroxymethyl)‑4‑(3‑methoxyphenyl)pyrrolidine, a key intermediate for P‑chiral phosphoramidite ligands used in iridium‑catalysed asymmetric allylic alkylation. The reduction is carried out in a 1000 L stirred vessel under a nitrogen pad with a pre‑dried (KF ≤ 50 ppm) THF solution of the substrate cooled to −10°C. Lithium aluminium hydride powder (2.5 molar equivalents, added in 5 portions over 90 min to maintain the internal temperature below 0°C) necessitates a Fauske vent‑sizing analysis per DIERS methodology because hydrogen off‑gas generation and the exotherm demand an emergency relief area of 0.08 m² for a 10‑bar design pressure. After completion, the reaction is quenched sequentially with water (1.0 mL per gram LiAlH₄), 15% aqueous sodium hydroxide (1.0 mL/g), and water again (3.0 mL/g), and the granular precipitate is removed through a 0.5 µm in‑line PTFE filter. The amino alcohol, isolated after solvent swap to isopropyl acetate and crystallisation at −15°C with 97% recovered yield and 99.4% ee (Chiralpak AD‑H, 80:20 hexane:isopropanol), is then converted to the phosphoramidite ligand by reaction with hexamethylphosphorous triamide (1.05 eq) in toluene at 80°C for 3 h. In the downstream asymmetric allylic alkylation of (E)‑1,3‑diphenylallyl acetate with dimethyl malonate, the iridium‑phosphoramidite catalyst generated in situ from [Ir(COD)Cl]₂ (2 mol% Ir) and the ligand (4 mol%) delivers the allylation product in 94% isolated yield and 97% ee at a substrate concentration of 0.5 M in dichloromethane at 25°C over 18 h (monitored by HPLC, Phenomenex Luna C18, acetonitrile/water 70:30). Process mass intensity for the ligand synthesis is driven largely by the lithium aluminium hydride work‑up; replacing the classic Fieser quench with an aqueous Rochelle’s salt extraction reduces the PMI from 82 to 56 in pilot‑scale trials. The ligand is supplied as a non‑GMP research chemical under ISO 9001:2015 certification with a certificate of analysis documenting specific optical rotation ([α]D²⁰ = +72.3°, c 1.0, CHCl₃), ³¹P NMR purity (≥ 98%), and residual elemental impurities compliant with ICH Q3D Option 2 limits.

Fmoc‑protected (3S,4R)‑4‑(3‑methoxyphenyl)pyrrolidine‑3‑carboxylic acid—prepared by reacting the parent acid with Fmoc‑OSu (1.05 eq) in dioxane/water (2:1) at 0°C with sodium carbonate (2.2 eq)—is integrated into resin‑bound peptide sequences on a 0.1 mmol scale using automated microwave‑assisted solid‑phase synthesis (CEM Liberty Blue, 50°C, 20 W power). The building block is coupled with 2.0 equivalents relative to resin loading, activated with 2‑(6‑chloro‑1H‑benzotriazol‑1‑yl)‑1,1,3,3‑tetramethylaminium hexafluorophosphate (HCTU, 2.0 eq) and N,N‑diisopropylethylamine (4.0 eq) in N‑methyl‑2‑pyrrolidone for 5 min of pre‑activation followed by 10 min coupling. Deprotection of the Fmoc group uses 20% piperidine in DMF (2 × 5 min). The (3S,4R) stereochemistry imposes a cis orientation of the 3‑carboxamide bond and the 4‑aryl group, which rigidifies β‑turn motifs in macrocyclic heptapeptides screened as CXCR4 antagonists. After global deprotection with trifluoroacetic acid/triisopropylsilane/water (95:2.5:2.5) for 2.5 h at 25°C, the crude peptide is precipitated in cold diethyl ether and purified by reversed‑phase preparative HPLC (Phenomenex Jupiter C18, 250×21.2 mm, gradient 10→60% acetonitrile in water with 0.1% TFA). The fraction containing the target macrocycle is lyophilised to yield a trifluoroacetate salt with a purity of ≥ 95% (analytical HPLC at 220 nm). Specification compliance for the Fmoc‑pyrrolidine acid adheres to the Ph.Eur. general monograph 2034 for synthetic peptide reagents, with residual DMF controlled to ≤ 1000 ppm (headspace GC‑FID) and chiral purity confirmed at 99.2% ee. Process observations on Wang resin with a loading of 0.8 mmol/g at 50°C show that the steric bulk of the 3‑methoxyphenyl group reduces the coupling efficiency to 88–92% per cycle, requiring a double‑coupling protocol for peptide positions immediately preceding the pyrrolidine residue.

If the Methoxyphenyl Substituent Survives into the Drug Substance, Elemental Impurity Risk Is Assessed per ICH Q3D Option 2a

When the (3S,4R)‑4‑(3‑methoxyphenyl)pyrrolidine‑3‑carboxylic acid intermediate is processed to a final active pharmaceutical ingredient where the 3‑methoxyphenyl pharmacophore remains intact—as occurs in certain σ‑1 receptor ligands advanced for neuropathic pain—elemental impurity control becomes integral to the synthetic route scouting. The acid itself is sourced with an elemental impurity profile audited against the ICH Q3D classification for oral drug products (Permitted Daily Exposure for palladium 100 µg/day, nickel 200 µg/day, and chromium 11,000 µg/day). A specification limit of ≤ 20 µg/g total palladium (USP 〈232〉) is enforced on the incoming intermediate because the subsequent hydrogenolysis of the methyl ether to the phenol utilises 5% Pd/Al₂O₃ catalyst (0.5% w/w substrate) in tetrahydrofuran at 25°C and 2 bar H₂. In the final drug substance manufacture, the carboxamide coupling between the pyrrolidine‑derived phenol and a 2‑halo‑acetamide is performed with 1.02 eq of the phenol to limit over‑alkylation, using potassium carbonate (2.5 eq) in acetonitrile at 60°C for 8 h. Residual solvent analysis for this final step follows ICH Q3C limits for Class 2 solvents (acetonitrile 410 ppm), verified by headspace GC‑FID on a DB‑624 column (30 m × 0.53 mm, 3.0 µm). Excipient compatibility screening for tabletting shows that the API derived from this intermediate, when formulated as a dry‑granulated blend with microcrystalline cellulose (50% w/w), lactose monohydrate (25.5% w/w), croscarmellose sodium (3% w/w), and magnesium stearate (1.5% w/w), yields a tablet with a core weight of 400 mg containing 80 mg of API (i.e., 20% drug load). Dissolution testing per USP 〈711〉 apparatus II (50 rpm, 900 mL pH 6.8 phosphate buffer) demonstrates ≥ 85% release at 30 min for tablets compressed at 12 kN on a rotary press. A critical assignable cause limitation surfaces during scale‑up: the phenolic intermediate derived from ether cleavage is prone to oxidative discolouration when exposed to headspace oxygen above 5% v/v in the reactor, necessitating a nitrogen overlay of ≥ 99.9% purity and the addition of 0.02% w/w butylated hydroxytoluene as an antioxidant, permissible under 21 CFR 182.3173.

In fragment-based drug discovery and parallel library synthesis, (3S,4R)-4-(3-methoxyphenyl)pyrrolidine-3-carboxylic acid is delivered as a pre‑weighed, barcode‑tracked array building block in 96‑well microtiter plate format, each well containing 50 µmol of dry solid sealed under argon. The building block is utilised directly in a high‑throughput amide‑formation protocol employing a liquid handler that dispenses DMF stock solutions of the amine diversity reagents (0.2 M, 0.95 eq relative to the acid), followed by addition of benzotriazol‑1‑yl‑oxytripyrrolidinophosphonium hexafluorophosphate (0.9 eq, 0.6 M in DMF) and diisopropylethylamine (2.5 eq neat). Plates are sealed and agitated at 25°C for 16 h before the solvent is evaporated on a Genevac HT‑12 centrifugal evaporator (35°C, 8 mbar) and the residue purified by automated flash chromatography (Biotage® Isolera, SNAP Ultra C18 cartridges). Hit molecules emerging from this library are profiled for CYP450 inhibition (CYP3A4, 2D6, 2C9 isoforms) and hERG channel binding (flux assay, IC₅₀ cut‑off 10 µM) before nomination for lead optimisation. Quality control of the dispensed acid building block under the ISO 17025‑accredited analytical facility includes chiral LC‑MS confirmation (99.0% ee) and gravimetric verification of the well content with a tolerance of ± 5%. Throughout the library production campaign, three control wells per 96‑well plate are spiked with an internal standard (4‑biphenylcarboxylic acid) to monitor coupling consistency; a well is flagged for re‑synthesis if the residual acid peak exceeds 15% of the standard‑normalised value, indicative of incomplete activation possibly caused by ambient moisture ingression into the DMF reservoir beyond 300 ppm water.